BR0209035A - Antagonistas de receptor crf - Google Patents

Antagonistas de receptor crf

Info

Publication number
BR0209035A
BR0209035A BR0209035-0A BR0209035A BR0209035A BR 0209035 A BR0209035 A BR 0209035A BR 0209035 A BR0209035 A BR 0209035A BR 0209035 A BR0209035 A BR 0209035A
Authority
BR
Brazil
Prior art keywords
halo
alkyl
alkoxy
alkynyl
alkenyl
Prior art date
Application number
BR0209035-0A
Other languages
English (en)
Inventor
Romano Di Fabio
Fabrizio Micheli
Alessandra Pasquarello
Yves St-Denis
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0110579A external-priority patent/GB0110579D0/en
Priority claimed from GB0110566A external-priority patent/GB0110566D0/en
Priority claimed from GB0117423A external-priority patent/GB0117423D0/en
Priority claimed from GB0203203A external-priority patent/GB0203203D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR0209035A publication Critical patent/BR0209035A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16Peri-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"ANTAGONISTAS DE RECEPTOR CRF". A presente invenção diz respeito a compostos de pirimidinas tricíclicas de fórmula (I), incluindo esteroisómeros, profármacos e sais ou solvatos farmaceuticamente aceitáveis destes, em que R é arila ou heteroarila, em que, em cada um dos grupos apresentados, R pode ser substituído por 1 a 4 substituintes selecionados independentemente do grupo que consiste de: halogênio, C1-C6 alquila, C1-C6 alcóxi, halo C1-C6 alquila, C1-C6 alquenila, C1-C6 alquinila, halo C1-C6 alcóxi, C1-C6 mono ou dialquilamino, nitro, ciano e um grupo R~ 4~; R~ 1~ é hidrogênio, C1-C6 alquila, C1-C6 alquenila, C1-C6 alquinila, halo C1-C6 alquila, halo C1-C6 alcóxi, NH~ 2~, halogênio ou ciano; R~ 2~ é hidrogênio ou C(H)~ n~n(R~ 5~)~ q~(CH~ 2~)pZR~ 6~: R~ 1~ é hidrogênio, C2-C6 alquenila, C2-C6 alquinila ou [CH (R~ 5~) (CH~ 2~)]~ m~ZR~ 6~; R~ 4~ é C3 -C7 cicloalquila, que pode conter uma ou mais ligações duplas; arila; ou um heterociclo 5-6 membrado; em que, em cada um dos grupos apresentados, R~ 4~ pode ser substituído por um ou mais grupos selecionados de: halogênio, C1-C6 alquila, C1-C6 alcóxi, halo C1-C6 alquila, C2-C6 alquenila, C2-C6 alquinila, halo C1-C6 alcóxi, C1-C6 mona ou dialquilamino, nitro, e ciano; R~ 5~ é hidrogênio, C2-C6 alquenila, C2-C6 alquinila ou (CH~ 2~)pZR~ 6~; R~ 6~ é C1-C6 alquila, que pode ser substituído por um ou mais grupos selecionados de halogênio, halo C1-C6 alquila, C2-C6 alquenila, C2-C6 alquinila, halo C1-C6 alcóxi, C1-C6 alcóxi, C1-C6 mono ou dialquilamino, nitro, ciano e um grupo R~ 4~; Y e X são independentemente carbono ou nitrogênio; m e n são independentemente 0 ou 1; p é 0 ou um número inteiro de 1 a 4; q é 1 ou 2; Z é uma ligação 0, NH ou S; a processos para sua preparação, a composições farmacêuticas que os contém e seus usos no tratamento de condições mediadas por fator de liberação de corticotropina (CRF).
BR0209035-0A 2001-04-30 2002-04-30 Antagonistas de receptor crf BR0209035A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0110579A GB0110579D0 (en) 2001-04-30 2001-04-30 Chemical compounds
GB0110566A GB0110566D0 (en) 2001-04-30 2001-04-30 Chemical compounds
GB0117423A GB0117423D0 (en) 2001-07-17 2001-07-17 Chemical compounds
GB0203203A GB0203203D0 (en) 2002-02-11 2002-02-11 Chemical compounds
PCT/GB2002/001981 WO2002087573A1 (en) 2001-04-30 2002-04-30 Crf receptor antagonists

Publications (1)

Publication Number Publication Date
BR0209035A true BR0209035A (pt) 2004-08-10

Family

ID=27447943

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0209035-0A BR0209035A (pt) 2001-04-30 2002-04-30 Antagonistas de receptor crf

Country Status (21)

Country Link
US (1) US7329667B2 (pt)
EP (1) EP1383498B1 (pt)
JP (1) JP2004528342A (pt)
KR (1) KR20040015205A (pt)
CN (1) CN1512883A (pt)
AR (1) AR033296A1 (pt)
AT (1) ATE320254T1 (pt)
AU (1) AU2002249474B2 (pt)
BR (1) BR0209035A (pt)
CA (1) CA2446497A1 (pt)
CZ (1) CZ20032945A3 (pt)
DE (1) DE60209885T2 (pt)
ES (1) ES2255610T3 (pt)
HU (1) HUP0304035A2 (pt)
IL (1) IL158063A0 (pt)
MX (1) MXPA03009930A (pt)
NO (1) NO20034837L (pt)
NZ (1) NZ528364A (pt)
PL (1) PL366854A1 (pt)
TW (1) TWI236908B (pt)
WO (1) WO2002087573A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
ES2540964T3 (es) 2009-06-08 2015-07-15 Takeda Pharmaceutical Company Limited Compuestos de dihidropirrolonaftiridinona como inhibidores de JAK
RU2498986C2 (ru) * 2011-07-20 2013-11-20 Учреждение Российской Академии Наук Институт Проблем Химической Физики Ран (Ипхф Ран) ТЕТРАЦИАНОЗАМЕЩЕННЫЕ 1,4,9b-ТРИАЗАФЕНАЛЕНЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403599B1 (en) * 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
ZA973884B (en) * 1996-05-23 1998-11-06 Du Pont Merck Pharma Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders
IL142893A0 (en) * 1998-11-12 2002-04-21 Neurocrine Biosciences Inc Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
DE69908173T2 (de) * 1998-11-12 2004-08-19 Neurocrine Biosciences, Inc., San Diego Crf rezeptor-antagonisten und darauf bezogene methoden
GB0117395D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
AR033296A1 (es) 2003-12-10
ATE320254T1 (de) 2006-04-15
ES2255610T3 (es) 2006-07-01
NZ528364A (en) 2005-12-23
DE60209885T2 (de) 2006-08-10
DE60209885D1 (de) 2006-05-11
EP1383498A1 (en) 2004-01-28
CZ20032945A3 (cs) 2004-02-18
JP2004528342A (ja) 2004-09-16
CA2446497A1 (en) 2002-11-07
US20040235871A1 (en) 2004-11-25
KR20040015205A (ko) 2004-02-18
AU2002249474B2 (en) 2006-01-12
MXPA03009930A (es) 2004-01-29
PL366854A1 (en) 2005-02-07
NO20034837D0 (no) 2003-10-29
US7329667B2 (en) 2008-02-12
EP1383498B1 (en) 2006-03-15
TWI236908B (en) 2005-08-01
HUP0304035A2 (hu) 2004-04-28
CN1512883A (zh) 2004-07-14
NO20034837L (no) 2003-12-09
IL158063A0 (en) 2004-03-28
WO2002087573A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
BRPI0409117A (pt) compostos n-heterocìclios condensados e seu uso como antagonistas do receptor de crf
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
NO20071109L (no) Indol-2-karboksamidinderivater som NMDA-reseptorantagonister
BR0308145A (pt) Composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
DE602004005960D1 (de) Heteroaryl-substituierte pyrrolä2, 3- büpyridin-derivate als crf-rezeptor-antagonisten
BR0211171A (pt) Compostos quìmicos
NO20040589L (no) Arylsulfonylderivater med 5-HT6 reseptor affinitet.
BRPI0315958B8 (pt) composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto
BRPI0517100A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, método para preparar um composto, composição farmacêutica, e, métodos para tratar um paciente sofrendo de distúrbios e de deficiência
DK1165544T3 (da) Substituerede 1,4-dihydroindeno[1,2-c]pyrazoler som inhibitorer af tyrosinkinase
ATE401080T1 (de) (3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
DE60318874D1 (en) Pyrazolderivate
BR0209035A (pt) Antagonistas de receptor crf
DE60226971D1 (de) Corticotropinfreisetzungsfaktor antagonisten
BR0207730A (pt) Derivados de ácido alcoxicarbonila-mino-heteroaril carboxìlico, como antagonistas de ip
DE60209014D1 (de) Tricylische CRF Rezeptorantagonisten
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
BR0314759A (pt) Derivados de pirazol
HK1075656A1 (en) New piperidinyl-alkylamino-pyridazinone derivatives, a process for the preparation thereof and pharmaceutical compositions containing said compounds
GB0223234D0 (en) Chemical compounds
CA2323315A1 (en) Process for the preparation of piperidinylaminomethyl trifluoromethyl cyclic ether compounds
MXPA02012190A (es) N-(ciclopropilmetil) azacicloalcanos, composiciones que los contienen y metodos para su preparacion.
BRPI0417895B8 (pt) composto, processo para a preparação de um composto e uso do composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 6A., 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.